Preferred Label : Autologous PD-1 Nanobody-expressing Anti-MSLN CAR T-cells;
NCIt synonyms : Autologous PD-1 Nanobody-expressing Anti-Mesothelin CAR-T Cells; alphaPD1-MSLN-CAR T Cells; aPD1-MSLN-CAR T Cells; alpha-PD1-MSLN-CAR T Cells; a-PD1-MSLN-CAR T Cells; PD-1 Nanobody-expressing Anti-MSLN CAR T-cells;
NCIt definition : A preparation of autologous T-lymphocytes that have been genetically modified to express
a nanobody that targets the negative immunoregulatory human cell surface receptor
programmed cell death protein 1 (PD-1; PDCD1; CD279) and transduced with a gene encoding
a chimeric antigen receptor (CAR) specific for the human tumor-associated antigen
(TAA) mesothelin (MSLN), with potential immunomodulating and antineoplastic activities.
After isolation, transduction, expansion in culture, and reintroduction into the patient,
the autologous PD-1 nanobody-expressing anti-MSLN CAR T-cells specifically target
and kill MSLN-expressing tumor cells. The anti-PD-1 expressed on the CAR T-cells binds
to PD-1 expressed on T-cells and prevents the interaction of PD-1 with its ligand
programmed cell death 1 ligand 1 (PD-L1, PD-1L1; CD274) expressed on tumor cells.
This prevents PD-1-mediated signaling and T-cell exhaustion, enhances T-cell activation,
and results in enhanced toxicity in MSLN-expressing tumor cells. PD-1, an immunoglobulin
(Ig) superfamily transmembrane protein and inhibitory receptor, negatively regulates
T-cell activation and overexpression within the tumor microenvironment (TME) and inhibits
T-cell function. MSLN, a cell surface glycoprotein involved in cell adhesion, is overexpressed
in a variety of cancer cell types.;
NCI Metathesaurus CUI : CL1647818;
Origin ID : C178316;
UMLS CUI : C5554942;
Semantic type(s)
- Cell [UMLS semantic type]
- chemical_or_drug_affects_cell_type_or_tissue
- chemical_or_drug_has_mechanism_of_action
- chemical_or_drug_has_physiologic_effect
- concept_is_in_subset
- has_target
